07:00 , May 25, 2015 |  BC Week In Review  |  Company News

Aspireo, Cortendo deal

Cortendo will acquire Somatoprim ( DG3173 ) from Aspireo for $30 million in Cortendo equity. The somatostatin analog that suppresses human growth hormone (hGH) secretion by targeting somatostatin receptors 2, 4 and 5 is in...
07:00 , Apr 8, 2013 |  BC Week In Review  |  Clinical News

Somatoprim: Phase IIa data

Top-line data from an open-label, Ukrainian Phase IIa trial in about 20 treatment-naïve patients with acromegaly showed that single ascending-doses of subcutaneous Somatoprim dose-dependently reduced hGH secretion. No serious adverse events were reported. Aspireo said...
08:00 , Jan 14, 2013 |  BC Week In Review  |  Clinical News

Somatoprim: Interim Phase Ib data

Interim data from a Phase Ib trial in healthy male volunteers showed that multiple ascending-doses of Somatoprim with and without octreotide led to no serious adverse events. Reported adverse events were generally mild to moderate...
08:00 , Nov 19, 2012 |  BC Week In Review  |  Clinical News

Somatoprim: Phase IIa started

Aspireo began an open-label, Ukrainian Phase IIa trial to evaluate single ascending-doses of 100, 300, 900 and 1,800 µg subcutaneous Somatoprim in combination with 300 µg octreotide in up to 20 untreated acromegaly patients. The...